EGFR and non-small cell lung carcinoma: A CMTM6‐targeting nanobody is developed and administration of this agent leads to blocking of the CMTM6‐EGFR interaction, reduction of the EGFR protein level, and inhibition of the proliferation of TKI‐resistant NSCLC cells in vitro and suppression of the growth of EGFR‐TKI‐resistant NSCLC in both cell line‐derived xenografts and patient‐derived xenograft models.